OrthoPediatrics (NASDAQ:KIDS – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04, Zacks reports. The firm had revenue of $52.67 million during the quarter, compared to the consensus estimate of $51.16 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. During the same quarter last year, the company posted ($0.23) EPS. OrthoPediatrics updated its FY 2025 guidance to EPS.
OrthoPediatrics Stock Up 11.9 %
Shares of NASDAQ KIDS opened at $25.61 on Thursday. The stock has a market capitalization of $620.17 million, a P/E ratio of -20.82 and a beta of 1.14. OrthoPediatrics has a one year low of $21.02 and a one year high of $35.99. The firm’s 50 day simple moving average is $24.45 and its two-hundred day simple moving average is $25.93. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on KIDS. Truist Financial dropped their target price on shares of OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th. Stifel Nicolaus dropped their price objective on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $42.00 target price on shares of OrthoPediatrics in a research note on Wednesday.
OrthoPediatrics Company Profile
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.
Further Reading
- Five stocks we like better than OrthoPediatrics
- EV Stocks and How to Profit from Them
- Robinhood’s Rally: Is Global Expansion the Next Big Catalyst?
- 3 Small Caps With Big Return Potential
- Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors
- What is a buyback in stocks? A comprehensive guide for investors
- Why Now Might Be the Best Time to Buy Target Stock
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
